Meeting
2022 ASCO Annual Meeting
A phase 1/2 study of RTX-224, an engineered red blood cell expressing 4-1BB ligand and membrane-bound IL-12, for the treatment of patients with select advanced solid tumors.
Authors
Alexander I. Spira
NEXT Oncology - Virginia Cancer Specialists, Fairfax, VA
Alexander I. Spira , Melissa Lynne Johnson , Ai Ren , Varsha Sundaresan , Ines Verdon , Laurence Turka , Sivan Elloul
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
NCT05219578
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS2680)
DOI
10.1200/JCO.2022.40.16_suppl.TPS2680
Abstract #
TPS2680
Poster Bd #
329a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Updated results from an ongoing phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via IT injection as monotherapy or combined with pembrolizumab in advanced solid tumors.
First Author: Jiaxin Niu
Poster
2023 ASCO Annual Meeting
A phase 1/2 study of retifanlimab (INCMGA00012, Anti–PD-1), INCAGN02385 (Anti–LAG-3), and INCAGN02390 (Anti–TIM-3) combination therapy in patients (Pts) with advanced solid tumors.
First Author: Omid Hamid
Poster
2022 ASCO Annual Meeting
AFM24 in combination with atezolizumab in patients with advanced EGFR-expressing solid tumors: Phase 1/2a study design and rationale.
First Author: Omar Saavedra Santa Gadea
Poster
2021 ASCO Annual Meeting
A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC410 in subjects with advanced or metastatic solid tumors.
First Author: Martin Gutierrez